Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

A legfontosabb adatok

Ki végzi
Travera Inc
Hol
Boston, Duarte és New York (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
33 fő vett részt
Kezdés
2019. febr. 11.
Befejezés
2024. jún. 30.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2024. július 3.
Miért állt le
Insufficient pace of enrollment due to changes in MM SOC practices

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Written Informed Consent provided by patient
  • MM, with the following conditions:; (CLOSED) *For patients in the Vanguard cohort*
  • Treatment naïve disease with BM clinically indicated; *For patients in the RRMM cohort*
  • Relapsed/refractory disease with BM samples clinically indicated
  • Within 4-weeks prior to initiation of 2nd-line or later therapy
  • Patient's oncologist must be planning to change the patient's next line of treatment to a monotherapy or combination therapy composed exclusively of drugs from the following list: Bortezomib (Velcade), Carfilzomib (Kyprolis), Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Cyclophosphamide (Cytoxan), Dexamethasone, Ixazomib (Ninlaro), Venetoclax (Venclexta), Selinexor (Xpovio)

Ki nem vehet részt

  • Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately planned treatment (as prior therapy is acceptable)
  • Prior exposure to CAR-T therapy
  • Prior allogeneic stem cell transplant
  • Has received any systemic chemotherapy or RT, including palliative, within 7 days prior to BM biopsy
  • Has received any Ab therapy within 4 weeks prior to BM biopsy
  • Unable or unwilling to provide informed consent
  • Patient enrolled/enrolling in a clinical trial where data or specimen sharing provisions preclude use in this study

Helyszínek itt: Egyesült Államok

  • Dana-Farber Cancer InstituteBoston, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • City of Hope Comprehensive Cancer CenterDuarte, Egyesült Államok
  • Weill Cornell Medicine | New York-PresbyterianNew York, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will collect bone marrow (BM) aspirate samples from patients with relapsed refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker of patient response to that regimen.

A teljes eredeti leírásKevesebb

The primary study objective is to explore whether the single-cell MAR biomarker can predict patient response in RRMM patients. In order to enable this primary objective, two patient cohorts will be required. First, a small vanguard cohort of patients with treatment naïve disease to define drug concentrations used for testing, and second, the main RRMM patient cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy, sensitivity, specificity), and to support improvement of the MAR biomarker through additional research and discovery within the study dataset.

A vizsgálat 2 csoportja

  • Vanguard

    (CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.

  • Relapsed/Refractory MM

    BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. július 3.